Employed by Investees
Co-investment and grants
We invest in innovative technologies.
We are a unique commercialisation fund helping researchers from our partner research organisations turn their ideas into products and services. We support innovations that solve market problems and create a positive impact for our community. Uniseed invests over a broad range of technology sectors and has exited six investments, to date.
How we help
Seed capital investment
We invest in your innovation to help you progress and de-risk from both a technical and commercial perspective.
We believe in supporting your progress through collaboration and mentoring.
You will have the ability to access Uniseed’s network of industry experts, co-investors and start-up experts.
We help you build your strategy, manage your intellectual property and identify commercial partners.
Rewards & recognition
Boost career profile, publications, conferences, patent publications and increase your visibility.
Make an impact
Impact our community by solving market problems through your innovation.
Our Process ›
Step 1: Make Contact
Get in contact through your commercialisation office or directly with us. Initial meetings and discussions will start with an Investment Manager. Tell us about your innovative opportunity and we will assist in identifying the most appropriate pathway forward.
Step 2: Pitch to Us
Promising eligible opportunities will have the opportunity to pitch to the Uniseed Investment Committees (which convenes monthly) and receive feedback.
Step 3: Due Diligence & Negotiation
Uniseed conducts detailed due diligence on your opportunity which may include further presentation(s) to our investment committee. We syndicate promising deals with your co-investors (as required)
Step 4: Investment & Growth
Investment capital is provided. Uniseed provides expert guidance and access to networks. We also help to develop, grow and scale your innovation.
Step 5: Impact & Exit
Generate impact through your innovation. Receive awards and recognition. Exit and achieve a return for shareholders.
Dr Jennifer Batson will present ‘A Paradigm Shift in the Treatment of Retinal Vascular Diseases’ at Pharmacology 2017 on Tuesday 12 December 2017 Exonate is developing eye drops to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK –...read more
27 November, Melbourne, Australia – Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot, has been granted in China. China is the latest in a growing list of countries where the patent has now...read more
Exonate announces the formation of ophthalmology Clinical Advisory Board Ophthalmology leaders to support early stage biotechnology company with potential to revolutionise current standard-of-care in the treatment of eye diseases Cambridge, UK – 8 November:...read more